TGFB1 and cancer: With recent developments in bifunctional approaches to perturb the immune system, specifically using TGFβ/PD-L1 (David et al, 2017; Lan et al, 2018; Ravi et al, 2018), modulating the ECM in cancers currently resistant to checkpoint inhibitor monotherapy may increase the efficacy.